- Home
- DHC vs KROS Comparison
DHC vs KROS Comparison
Compare DHC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHC | KROS |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | 585 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 584.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DHC | KROS |
|---|---|---|
| Price | $6.81 | $11.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $7.25 | ★ $22.25 |
| AVG Volume (30 Days) | ★ 2.0M | 430.8K |
| Earning Date | 05-04-2026 | 03-04-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | $3.13 | N/A |
| Revenue Next Year | $7.00 | $727.07 |
| P/E Ratio | ★ N/A | $4.78 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $9.12 |
| 52 Week High | $7.66 | $22.55 |
Technical Indicators
Market Signals| Indicator | DHC | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 31.58 |
| Support Level | $3.93 | $10.49 |
| Resistance Level | $6.85 | $16.12 |
| Average True Range (ATR) | 0.33 | 0.58 |
| MACD | -0.11 | 0.17 |
| Stochastic Oscillator | 30.31 | 72.48 |
Price Performance
Historical ComparisonAbout DHC Diversified Healthcare Trust of Beneficial Interest
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.